Homestead Advisers Corp Has $4.21 Million Position in Envista Holdings Co. (NYSE:NVST)

Homestead Advisers Corp raised its holdings in shares of Envista Holdings Co. (NYSE:NVST) by 20.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 218,300 shares of the company’s stock after purchasing an additional 36,700 shares during the quarter. Homestead Advisers Corp owned approximately 0.13% of Envista worth $4,211,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Venturi Wealth Management LLC boosted its stake in Envista by 528.4% in the 4th quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company’s stock valued at $38,000 after purchasing an additional 1,638 shares during the period. GAMMA Investing LLC raised its stake in Envista by 30.5% in the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company’s stock worth $44,000 after purchasing an additional 538 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Envista in the 4th quarter valued at about $53,000. Mitsubishi UFJ Trust & Banking Corp acquired a new position in shares of Envista during the 4th quarter worth approximately $86,000. Finally, KBC Group NV grew its position in Envista by 63.9% during the fourth quarter. KBC Group NV now owns 7,903 shares of the company’s stock worth $152,000 after buying an additional 3,082 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on NVST shares. Piper Sandler upped their target price on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. JPMorgan Chase & Co. lowered their target price on Envista from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Thursday, March 6th. UBS Group reduced their price target on shares of Envista from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Monday, March 10th. Jefferies Financial Group upped their price objective on shares of Envista from $20.00 to $22.00 and gave the stock a “hold” rating in a research report on Thursday, January 23rd. Finally, Mizuho began coverage on shares of Envista in a research note on Wednesday, December 4th. They set an “underperform” rating and a $20.00 target price on the stock. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Envista currently has an average rating of “Hold” and a consensus price target of $20.18.

Envista Stock Up 0.5 %

Shares of NYSE NVST opened at $17.55 on Thursday. Envista Holdings Co. has a 12-month low of $15.15 and a 12-month high of $23.00. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The firm has a market cap of $3.02 billion, a PE ratio of -2.70, a P/E/G ratio of 1.27 and a beta of 1.33. The company’s fifty day simple moving average is $19.67 and its 200 day simple moving average is $19.59.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. As a group, sell-side analysts forecast that Envista Holdings Co. will post 1 earnings per share for the current fiscal year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.